Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease.
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2013
At a glance
- Drugs Atorvastatin (Primary)
- Indications Coronary artery disease
- Focus Pharmacokinetics
- Acronyms ECGPPA
- 28 Nov 2011 Trial phase changed from II to I and actual patient number is 20 as reported by ClinicalTrials.gov.
- 28 Nov 2011 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.
- 28 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.